Literature DB >> 2845639

Estrogen receptors in gastric adenocarcinoma: a retrospective immunohistochemical analysis.

H Yokozaki1, N Takekura, A Takanashi, J Tabuchi, R Haruta, E Tahara.   

Abstract

Estrogen receptors (ER) in human gastric carcinomas were examined immunohistochemically using a specific monoclonal antibody to human ER. ER-immunoreactivity (ER-IR) was positive in 30 (27.8%) of the 108 gastric carcinomas examined. ER-IR was located in the nucleus of cancer cells. The incidence of ER-IR positive gastric carcinoma was not significantly different between male and female cases. However, the positive tumour cells were observed in 28 (39.4%) out of the 71 poorly differentiated adenocarcinoma, the incidence being significantly higher than that in well differentiated adenocarcinoma (p less than 0.01). There was no significant difference in the incidence of ER-IR between scirrhous carcinoma and non-scirrhous poorly differentiated adenocarcinoma. Synchronous expression of ER and epidermal growth factor receptor was found in 8 of the 26 scirrhous carcinomas (30.8%). Patients with ER-IR positive scirrhous gastric carcinomas showed a much worse prognosis than those with ER-IR negative scirrhous carcinomas.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2845639     DOI: 10.1007/bf00783021

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histopathol        ISSN: 0174-7398


  24 in total

1.  Hormone receptors in gastric cancer.

Authors:  A Tokunaga; N Kojima; T Andoh; N Matsukura; M Yoshiyasu; N Tanaka; K Ohkawa; A Shirota; G Asano; K Hayashi
Journal:  Eur J Cancer Clin Oncol       Date:  1983-05

2.  Are histochemical methods for estrogen receptor valid?

Authors:  G C Chamness; W D Mercer; W L McGuire
Journal:  J Histochem Cytochem       Date:  1980-08       Impact factor: 2.479

3.  Estrogen binding by neoplastic human thymus cytosol.

Authors:  F O Ranelletti; M Carmignani; P Marchetti; C Natoli; S Iacobelli
Journal:  Eur J Cancer       Date:  1980-07       Impact factor: 9.162

4.  Pathological review of breast lesions analyzed for estrogen receptor protein.

Authors:  P P Rosen; C J Menendez-Botet; J S Nisselbaum; J A Urban; V Miké; A Fracchia; M K Schwartz
Journal:  Cancer Res       Date:  1975-11       Impact factor: 12.701

5.  Estradiol and progesterone receptors in malignant gastrointestinal tumors.

Authors:  V Sica; E Nola; E Contieri; R Bova; M T Masucci; N Medici; A Petrillo; A Weisz; A M Molinari; G A Puca
Journal:  Cancer Res       Date:  1984-10       Impact factor: 12.701

6.  Estrogen and progesterone receptors in gastric cancer.

Authors:  A Tokunaga; K Nishi; N Matsukura; N Tanaka; M Onda; A Shirota; G Asano; K Hayashi
Journal:  Cancer       Date:  1986-04-01       Impact factor: 6.860

7.  Estrogen-receptor protein in intracranial meningiomas.

Authors:  M S Donnell; G A Meyer; W L Donegan
Journal:  J Neurosurg       Date:  1979-04       Impact factor: 5.115

8.  Steroid hormone receptors in human colon cancers.

Authors:  T C Alford; H M Do; G W Geelhoed; N T Tsangaris; M E Lippman
Journal:  Cancer       Date:  1979-03       Impact factor: 6.860

9.  Colonic neoplasms: tissue estrogen receptor and carcinoembryonic antigen.

Authors:  J E McClendon; D Appleby; D B Claudon; W L Donegan; J J DeCosse
Journal:  Arch Surg       Date:  1977-03

10.  Oestrogen receptors in human malignant melanoma.

Authors:  R I Fisher; J P Neifeld; M E Lippman
Journal:  Lancet       Date:  1976-08-14       Impact factor: 79.321

View more
  12 in total

Review 1.  Growth factors and oncogenes in human gastrointestinal carcinomas.

Authors:  E Tahara
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

2.  Oestrogen receptors in colorectal carcinoma.

Authors:  P M Dawson; S Shousha; S D Blair; G D Carter; J Jones; J Alaghband-Zadeh; N A Theodorou
Journal:  J Clin Pathol       Date:  1990-02       Impact factor: 3.411

3.  Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer.

Authors:  Lei Huo; Jinxia Zhang; Michael Z Gilcrease; Yun Gong; Yun Wu; Hong Zhang; Erika Resetkova; Kelly K Hunt; Michael T Deavers
Journal:  Histopathology       Date:  2012-09-11       Impact factor: 5.087

4.  The prognosis of patients with gastric cancer possessing sex hormone receptors.

Authors:  M Matsui; O Kojima; S Kawakami; Y Uehara; T Takahashi
Journal:  Surg Today       Date:  1992       Impact factor: 2.549

Review 5.  Estrogen receptors in gastric cancer: Advances and perspectives.

Authors:  Muhammad Saif Ur Rahman; Jiang Cao
Journal:  World J Gastroenterol       Date:  2016-02-28       Impact factor: 5.742

6.  Expression of oestrogen and progesterone receptors in gastric cancer: a flow cytometric study.

Authors:  D Karat; I Brotherick; B K Shenton; D Scott; S A Raimes; S M Griffin
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

7.  Metastatic carcinoma occurring in a gastric hyperplastic polyp mimicking primary gastric cancer: the first reported case.

Authors:  Gabriel M Groisman; Roman Depsames; Baruch Ovadia; Alona Meir
Journal:  Case Rep Pathol       Date:  2014-10-22

8.  Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer.

Authors:  Jun Ho Yi; In-Gu Do; Jiryeon Jang; Seung Tae Kim; Kyoung-Mee Kim; Se Hoon Park; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang; Jeeyun Lee
Journal:  Sci Rep       Date:  2014-12-23       Impact factor: 4.379

9.  Expression profile and prognostic role of sex hormone receptors in gastric cancer.

Authors:  Lu Gan; Jian He; Xia Zhang; Yong-Jie Zhang; Guan-Zhen Yu; Ying Chen; Jun Pan; Jie-Jun Wang; Xi Wang
Journal:  BMC Cancer       Date:  2012-12-02       Impact factor: 4.430

10.  Gastric metastases originating from occult breast lobular carcinoma: diagnostic and therapeutic problems.

Authors:  Antonio Ciulla; Gioacchino Castronovo; Giovanni Tomasello; Alfonso Maurizio Maiorana; Leila Russo; Elio Daniele; Gaspare Genova
Journal:  World J Surg Oncol       Date:  2008-07-25       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.